News

Daiichi Sankyo Company, Limited announced that it has successfully completed patient enrollment for its Phase III ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that is being investigated in two...

CardioComm Solutions, Inc. announced that they are completing a major rewrite of their Global ECG Management Software (GEMS™), and will have the Windows 7 forward-compatible GEMS 4.0 version available by the end of Q2 2011. It will be...

Boston Scientific Corporation announced CE Mark approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). They are the company's latest...

Campaign Calls for Urgent Action to Improve Patients' Health and Reduce Costs to National Health Systems The lives of thousands of patients with atrial fibrillation (AF) could be at risk due to poor diagnosis, failure to follow treatment...

Implanted devices that treat cardiac dysfunction in heart failure patients are as successful in "real world" use as they are in controlled clinical trial settings, according to a large new study reported in Circulation: Journal of the...

Medtronic, Inc. announced the publication of data showing that use of its Reveal® family of Insertable Cardiac Monitors led to diagnosis and specific treatment for 78 percent (170 of 218) of patients who experienced a recurrent syncopal...

Royal Philips Electronics, a worldwide leader in defibrillation technology, announced that its entire line of emergency care and resuscitation solutions supports the newly updated American Heart Association Guidelines for Cardiopulmonary...

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY® trial,(1) involving the newly approved oral anticoagulant Pradaxa® (dabigatran etexilate mesylate) capsules,(2) will be presented at the American Heart Association's...